S&P 500   3,980.97 (+0.25%)
DOW   32,463.41 (+0.70%)
QQQ   308.55 (-0.75%)
AAPL   158.61 (-1.02%)
MSFT   276.25 (-1.54%)
META   202.22 (-1.84%)
GOOGL   102.44 (-2.85%)
AMZN   97.43 (-0.71%)
TSLA   192.56 (+1.13%)
NVDA   264.28 (-1.31%)
NIO   8.93 (-1.54%)
BABA   85.74 (-1.33%)
AMD   95.87 (-2.12%)
T   18.86 (+1.34%)
F   11.52 (+0.09%)
MU   59.70 (-2.39%)
CGC   1.89 (-0.53%)
GE   93.02 (+1.81%)
DIS   94.97 (+0.95%)
AMC   4.36 (-2.46%)
PYPL   73.49 (-0.53%)
PFE   40.31 (-0.20%)
NFLX   329.17 (+0.24%)
S&P 500   3,980.97 (+0.25%)
DOW   32,463.41 (+0.70%)
QQQ   308.55 (-0.75%)
AAPL   158.61 (-1.02%)
MSFT   276.25 (-1.54%)
META   202.22 (-1.84%)
GOOGL   102.44 (-2.85%)
AMZN   97.43 (-0.71%)
TSLA   192.56 (+1.13%)
NVDA   264.28 (-1.31%)
NIO   8.93 (-1.54%)
BABA   85.74 (-1.33%)
AMD   95.87 (-2.12%)
T   18.86 (+1.34%)
F   11.52 (+0.09%)
MU   59.70 (-2.39%)
CGC   1.89 (-0.53%)
GE   93.02 (+1.81%)
DIS   94.97 (+0.95%)
AMC   4.36 (-2.46%)
PYPL   73.49 (-0.53%)
PFE   40.31 (-0.20%)
NFLX   329.17 (+0.24%)
S&P 500   3,980.97 (+0.25%)
DOW   32,463.41 (+0.70%)
QQQ   308.55 (-0.75%)
AAPL   158.61 (-1.02%)
MSFT   276.25 (-1.54%)
META   202.22 (-1.84%)
GOOGL   102.44 (-2.85%)
AMZN   97.43 (-0.71%)
TSLA   192.56 (+1.13%)
NVDA   264.28 (-1.31%)
NIO   8.93 (-1.54%)
BABA   85.74 (-1.33%)
AMD   95.87 (-2.12%)
T   18.86 (+1.34%)
F   11.52 (+0.09%)
MU   59.70 (-2.39%)
CGC   1.89 (-0.53%)
GE   93.02 (+1.81%)
DIS   94.97 (+0.95%)
AMC   4.36 (-2.46%)
PYPL   73.49 (-0.53%)
PFE   40.31 (-0.20%)
NFLX   329.17 (+0.24%)
S&P 500   3,980.97 (+0.25%)
DOW   32,463.41 (+0.70%)
QQQ   308.55 (-0.75%)
AAPL   158.61 (-1.02%)
MSFT   276.25 (-1.54%)
META   202.22 (-1.84%)
GOOGL   102.44 (-2.85%)
AMZN   97.43 (-0.71%)
TSLA   192.56 (+1.13%)
NVDA   264.28 (-1.31%)
NIO   8.93 (-1.54%)
BABA   85.74 (-1.33%)
AMD   95.87 (-2.12%)
T   18.86 (+1.34%)
F   11.52 (+0.09%)
MU   59.70 (-2.39%)
CGC   1.89 (-0.53%)
GE   93.02 (+1.81%)
DIS   94.97 (+0.95%)
AMC   4.36 (-2.46%)
PYPL   73.49 (-0.53%)
PFE   40.31 (-0.20%)
NFLX   329.17 (+0.24%)
OTCMKTS:DMCAF

DiaMedica Therapeutics - DMCAF Stock Forecast, Price & News

$1.59
+0.08 (+5.30%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.47
▼
$1.59
50-Day Range
$1.35
▼
$1.89
52-Week Range
$0.38
▼
$0.38
Volume
15,843 shs
Average Volume
131,151 shs
Market Capitalization
$249.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

DMCAF stock logo

About DiaMedica Therapeutics (OTCMKTS:DMCAF) Stock

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Receive DMCAF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DMCAF Stock News Headlines

March 19, 2023 | americanbankingnews.com
DiaMedica Therapeutics (OTCMKTS:DMCAF) Trading 6.2% Higher
November 2, 2022 | msn.com
What Makes DiaMedica Therapeutics, Inc. (DMAC) a New Buy Stock
March 27, 2023 | Legacy Research (Affiliate) (Ad)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
August 12, 2022 | seekingalpha.com
Diamedica Therapeutics GAAP EPS of -$0.13
August 11, 2022 | seekingalpha.com
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2022 Results - Earnings Call Transcript
October 30, 2019 | www.bloomberg.com
DiaMedica Therapeutics and Ahon Pharma, a Fosun Pharma Portfolio Company, Announces Signing of License Agreement for DM199 in C
June 20, 2019 | feeds.benzinga.com
What's Pushing Nano-Cap Biotech DiaMedica's Shares Higher?
May 14, 2019 | seekingalpha.com
DiaMedica Therapeutics Inc. (DMCAF) CEO Rick Pauls on Q1 2019 Results - Earnings Call Transcript
See More Headlines
Receive DMCAF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:DMCAF
CUSIP
N/A
CIK
N/A
Web
www.diamedica.com
Phone
763-496-5454
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
157,140,000
Free Float
N/A
Market Cap
$249.85 million
Optionable
Not Optionable
Beta
-0.02

Key Executives

  • Mr. Rick Pauls MBA (Age 47)
    CEO, Pres & Director
  • Dr. Todd A. Verdoorn Ph.D.
    Chief Scientific Officer
  • Mr. Scott B. Kellen (Age 53)
    CFO & Company Sec.
  • Mr. Edward B. Rady (Age 69)
    Chief Commercial Advisor
  • Dr. Dennis D. Kim M.D. (Age 48)
    MBA, Consulting Chief Medical Officer

Key Competitors

View All Competitors













DMCAF Stock - Frequently Asked Questions

How have DMCAF shares performed in 2023?

DiaMedica Therapeutics' stock was trading at $1.5801 at the start of the year. Since then, DMCAF stock has increased by 0.6% and is now trading at $1.59.
View the best growth stocks for 2023 here.

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the OTCMKTS under the ticker symbol "DMCAF."

How do I buy shares of DiaMedica Therapeutics?

Shares of DMCAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DiaMedica Therapeutics' stock price today?

One share of DMCAF stock can currently be purchased for approximately $1.59.

How much money does DiaMedica Therapeutics make?

DiaMedica Therapeutics (OTCMKTS:DMCAF) has a market capitalization of $249.85 million.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 Carlson Parkway Suite 260, Minneapolis MN, 55447. The official website for the company is www.diamedica.com. The company can be reached via phone at 763-496-5454 or via email at ppapi@diamedica.com.

This page (OTCMKTS:DMCAF) was last updated on 3/27/2023 by MarketBeat.com Staff